Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Sockel

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Blood|May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
British Journal of Haematology|November 13, 2024
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndromeCarmelo Gurnari, Elisa Galossi, Eleonora Lumia, et al.
The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.
American Journal of Hematology|October 2, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA TrialKatja Sockel, Christoph Röllig, Anke Mütherig, et al.
The Lancet. Haematology|June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCarmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Bone Marrow Transplantation|April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committeeChristopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Blood|May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
British Journal of Haematology|November 13, 2024
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndromeCarmelo Gurnari, Elisa Galossi, Eleonora Lumia, et al.
The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.
American Journal of Hematology|October 2, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA TrialKatja Sockel, Christoph Röllig, Anke Mütherig, et al.
The Lancet. Haematology|June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCarmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Bone Marrow Transplantation|April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committeeChristopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
Pageof 10